Nalpropion Pharmaceuticals

Nalpropion was established to acquire all commercial assets of Orexigen. Nalpropion is a biopharmaceutical company focused on weight loss treatments. CONTRAVE (naltrexone hydrochloride and bupropion extended-release) was approved in the United States in September 2014 and has been the most prescribed obesity medication since June 2015.